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Seeking similarities rather than differences with adults to aid in therapeutic advancement
for children
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2
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Commentary on Singh et al. “Response similarity assessment between polyarticular juvenile
idiopathic arthritis and adult rheumatoid arthritis for biologics” PMID 33626206

Drug development for children continues to lag behind that in adults, particularly in
neonatal and rare disease populations.(1) Historical reasons include economic incentives,
regulatory barriers, scarcity of widespread expertise in the conduct of pediatric clinical trials, a
paucity of known biomarkers in children, a conservative ethical framework, and lack of
consensus for a widely accepted development path. Ontogeny of drug biotransformation and
response is also a key factor unique to children that makes drug development hard. Physiologic
changes spanning infancy through adolescence can differentially impact drug pharmacokinetics
(PK). Age and disease-specific factors impacting pharmacodynamics (PD) are equally important
but often elusive, especially in rare rheumatic conditions.
Despite these inherent challenges, since the approval of the Best Pharmaceuticals for
Children Act (BPCA) and Pediatric Research Equity Act (PREA), there has been an increase in
both the number of clinical trials conducted in pediatrics and number of regulatory approvals for
indications in children.(2) The importance of a favorable regulatory framework is indicated by the
larger number of pediatric supplemental indication approvals in the US and Europe compared to
Japan, which lacks comprehensive legislation to mandate or incentivize drug development in
children.(3) While the drivers ultimately come from specific regulatory and legislative directives,
the framework for such has been fostered by thought leaders within the FDA, academics, and
industry, often brought together in collaboratives such as IQ Consortium, Critical Path, and
Institute for Advanced Clinical Trials for Children (I-ACT).

Given the barriers to the conduction of pediatric clinical trials, use of extant adult data is
relevant to drug development in children as a strategy to demonstrate a drug is “reasonably safe
and effective” in children. A key tool has been a framework and decision tree outlined by the
FDA in the 2014 guidance on clinical pharmacology considerations for pediatric studies.(4)
Unless there is a reasonable assumption of similarity in 1) disease progression or 2) response
to intervention in both adults and children, there is no role for extrapolation. In contrast, if both
are present, there is the potential to bring in adult data to inform drug development in children.
Furthermore, if there is both a reasonable assumption of 1) similar exposure-response and 2) a
measurable drug concentration predictive of response, the drug qualifies for “full extrapolation”.
If one or both cannot be met, the drug pathway can use “partial extrapolation”. The practical
difference is that full extrapolation allows an adequate PK study in children to match a dose to
an exposure associated with efficacy in adults. Partial extrapolation extends requirements for
adequate dose ranging trial(s) that demonstrate the ability to reach a target PD effect. The EMA
has endorsed a similar philosophy, with a focus on the uncertainty that surrounds the
evidentiary base to make assessments of similarity in disease progression and exposure
response.(5) Simply put, extrapolation can serve as wind to the back of drug development in
children. The key consideration is relevancy of the specific adult data to the specific pediatric
indication.
It is against this background that the investigation outlined by Singh and colleagues
(PMID 33626206) is welcomed to advance therapeutics in polyarticular juvenile idiopathic
arthritis (pJIA). Juvenile idiopathic arthritis (JIA) in its heterogeneous entirety is the most
common chronic rheumatic disease of childhood, however, the absolute number of patients with
the polyarticular subset of JIA (arthritis affecting 5 or more joints) is smaller, with incidence of
0.3 to 6.5/100,000.(6) Robust efficacy clinical trials in pJIA are difficult to conduct due to
enrollment barriers secondary to both the rarity of the patient population and the scarcity of
subspecialty providers. In addition, the incorporation of a placebo arm and the latency for study
completion of large prospective clinical trials results is an unacceptable delay to access
important treatments; and as more therapeutic options exist, patients and providers have
greater access to alternative treatment options, further narrowing the eligible population for
clinical trials.(7) Therefore, extrapolation of data from adults to children is an exciting approach to
enhance access to effective drugs; however, the gap in knowledge regarding similarities in
exposure and response in pJIA remained a significant obstacle to qualify for “full extrapolation”.
Singh sought to examine the exposure-response relationship for biologic agents in adult RA and
pJIA by extracting PK and clinical data from 9 phase II-III clinical trials for 4 approved RA

biological products and 4 randomized pivotal JIA trials (3 of which were double blind withdrawal
studies). The analysis examined 4 different biologic products (infliximab, adalimumab,
golimumab, and tocilizumab) with two different biologic targets well characterized in RA and JIA
(tumor necrosis factor-alpha and interleukin-6). Two products (infliximab and golimumab)
approved in rheumatoid arthritis (RA) failed to meet the primary endpoint in pJIA.
Drug exposures for all agents in pediatric patients were similar or higher compared to
adults, with the exception of children ≤ 35 kg receiving 3 mg/kg dosing of infliximab. This is
interesting and potentially important in light of the fact that the placebo-controlled RCT of
infliximab in pJIA did not meet its primary endpoint leading to a lack of labeling for pJIA despite
its notable effectiveness and use off-label in children.(8) Age or development-related differences
in drug disposition may play a role with infliximab, supported by reports of an inverse
relationship between age and infliximab clearance in JIA,(9) as well as the need for higher doses
to reach adequate drug trough concentrations in younger patients with inflammatory bowel
disease.(10)
Exposure–response was then explored utilizing the subcomponents of the composite
American College of Rheumatology core set criteria (ACR20 in RA and pACR30 in JIA), two
widely accepted validated outcome measures. Although they differ somewhat, several core
components of the composite measures overlap. Of the products investigated, only the failed
pJIA infliximab trial could be compared directly as it was similar in design to the adult studies,
and response for many measures when overlaid with adults was similar in children, even when
data were stratified by weight and corrected for placebo response. The one subcomponent that
was notably different was the physician assessment of overall disease activity, which
interestingly had a less robust change from baseline compared to adults, and begs the question:
for a subjective measure such as this, are there inherent differences in how providers rate
disease activity between adults and children? For the 3 other products, pediatric-specific trials
were conducted through a double blind withdrawal design, thus only data from the open label
phase of the trials were compared to adult data. Again, pediatric patients had similar or better
percentage improvement for the core clinical response subcomponents at similar drug
exposures to adults. A major criticism of the double blind withdrawal design is the potential to
overestimate the treatment effect towards responders by excluding non-responders prior to
randomization and in drugs with a long half-life (such as golimumab) where there may be a
carryover effect from the treatment period into the double blind withdrawal period.(7) Supportive
of such, golimumab did not achieve the primary endpoint in the pivotal trial in pJIA trial,(11) where
a prolonged treatment effect into the double blind withdrawal period may have contributed to

similar flare rates and clinical remission rates between active drug and placebo groups. Despite
this, its recent approval in pJIA was based on the open label, single arm GO-VIVA phase 3
clinical trial in children with pJIA and juvenile psoriatic arthritis enrolled across 9 countries and
similarities in exposure and response compared to 2 pivotal phase 3 trials in adults. In this line
of thought, recognizing the challenges in conducting and executing traditional RCTs in children
with rare disease, the authors take the approach of gathering a broad base of high quality
exposure and response data across different drugs and individual drug classes, and they are
the first to compare response and exposure systematically with similar response criteria
between RA and pJIA. This bridges an important gap in knowledge that has limited prior
qualifications for full extrapolation. Their approach of quantitative methods has been advocated
to test the strength of underlying assumptions of extrapolation.(12)
Despite this great step forward, challenges remain. Response rates even with the
current options leave many patients with suboptimal control of their symptoms and at risk for
long term morbidity and disability. Median AUCss values will not capture the patients who, for yet
unrecognized reasons, require personalized drug dosing. We cannot yet predict at onset which
individual patient requires which target-specific therapy, and new disease targets continue to be
discovered as the pathophysiology of these conditions are revealed. Additionally, although the
assumption of similarity of treatment response to drug exposure generally held, RA and pJIA
are not the same disease. Besides the unique contribution of ontogeny upon drug
biotransformation in children, there are also differences in inflammatory patterns, biomarker
expression,(13) and natural history.(14) Polyarticular JIA is but one subtype that resides under the
clinically heterogeneous umbrella diagnosis JIA, and it is recently recognized that the current
clinical and age-driven disease classification for JIA may need to be reconsidered and ultimately
driven by a more biologic basis.(15-17) It is the genetic and biologic similarity between pJIA and
RA that further justifies extrapolation as a mechanism for drug approval in children. It is possible
that in the future with ongoing identification of meaningful biomarkers of drug response,
endotypic classification according to the underlying biologic mechanism and response to
treatment could drive more precise and efficient management of children and adults alike.(18)
However, in our current state, the approach that Singh and colleagues took to capitalize on PKPD data from pivotal clinical trials to support exposure-response similarities between RA and
pJIA is the type of innovative approach we need to move the field forward and promote safe and
effective therapeutics to children who need them.
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